InMed Pharmaceuticals Inc.

DB:MWG Stock Report

Market Cap: €3.1m

InMed Pharmaceuticals Management

Management criteria checks 2/4

InMed Pharmaceuticals' CEO is Eric Adams, appointed in Jun 2016, has a tenure of 8.42 years. total yearly compensation is $415.40K, comprised of 70.8% salary and 29.2% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth €9.44K. The average tenure of the management team and the board of directors is 4 years and 2.5 years respectively.

Key information

Eric Adams

Chief executive officer

US$415.4k

Total compensation

CEO salary percentage70.8%
CEO tenure8.4yrs
CEO ownership0.3%
Management average tenure4yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Eric Adams's remuneration changed compared to InMed Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$7m

Jun 30 2024US$415kUS$294k

-US$8m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023n/an/a

-US$6m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023US$368kUS$278k

-US$8m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022n/an/a

-US$17m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022US$468kUS$363k

-US$19m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021n/an/a

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021US$735kUS$328k

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020n/an/a

-US$7m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020US$424kUS$287k

-US$9m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019n/an/a

-US$11m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019US$1mUS$287k

-US$10m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018n/an/a

-US$8m

Sep 30 2018n/an/a

-US$7m

Jun 30 2018US$2mUS$240k

-US$6m

Compensation vs Market: Eric's total compensation ($USD415.40K) is about average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.

CEO

Eric Adams (60 yo)

8.4yrs

Tenure

US$415,400

Compensation

Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences...

Leadership Team

NamePositionTenureCompensationOwnership
Eric Adams
President8.4yrsUS$415.40k0.31%
€ 9.4k
N. Jagpal
CFO & Corporate Secretaryless than a yearUS$274.85k0%
€ 0
Michael Woudenberg
Chief Operating Officer2.3yrsUS$349.20k0.00014%
€ 4.3
Alexandra Mancini
Senior Vice President of Clinical & Regulatory Affairs8.1yrsUS$313.60k0%
€ 0
Eric Hsu
Senior Vice President of Preclinical Research & Development6.7yrsUS$322.50k0.00042%
€ 13.0
Sazzad Hossain
Co-Founderno dataUS$142.43kno data
Sarah Li
VP of Accounting & Controller4.8yrsno datano data
Colin Clancy
Senior Director of Investor Relationsno datano datano data
Jerry Griffin
Vice President of Sales & Marketing2.8yrsno datano data
Shane Johnson
Senior VP & GM of BayMedica3.1yrsno datano data
Ado Muhammad
Senior Consultant of Medical Affairsno datano datano data

4.0yrs

Average Tenure

57.5yo

Average Age

Experienced Management: MWG's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Eric Adams
President8.4yrsUS$415.40k0.31%
€ 9.4k
Andrew Hull
Independent Chair of the Board8.2yrsUS$77.50k0.27%
€ 8.2k
Bryan Baldasare
Independent Director2.5yrsUS$52.50k0%
€ 0
Barry Greenberg
Member of the Scientific Advisory Boardless than a yearno datano data
Janet Grove
Independent Director2.8yrsUS$52.50k0%
€ 0
Nicole Lemerond
Independent Director2.3yrsUS$52.50k0%
€ 0
David Morgan
Member of Scientific Advisory Boardless than a yearno datano data

2.5yrs

Average Tenure

58.5yo

Average Age

Experienced Board: MWG's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.